Related Experiment Videos
[Influence of recombinant interleukin-2 on the course and pathomorphology of intraperitoneal staphylococcal infection
Abstract:
Resistance to the lethal doses of the infectious agent (3 DL100) develops in mice 6 days after the intraperitoneal non-lethal dose of staphylococcus in combination with recombinant interleukin-2 (RIL-2). This effect may be due to the activation of T- and B-dependent zones of the regional lymph nodes and spleen, activation and proliferation of the liver stellate reticulo-endotheliocytes, enhancement of the phagocytic activity of the circulating neutrophil granulocytes. These structural and functional mechanisms may be due to both direct RIL-2 effect in combination with an antigenic stimulation and indirect effect through other interleukins produced by lymphocytes activated by RIL-2.
Insights
Mice developed resistance to lethal Staphylococcus doses after receiving a non-lethal dose combined with recombinant interleukin-2 (RIL-2). This immune enhancement involved lymph node activation and increased phagocytic activity.
Area of Science:
- Immunology
- Microbiology
Context:
- Investigating the immunomodulatory effects of cytokines in bacterial infections.
- Exploring the role of recombinant interleukin-2 (RIL-2) in enhancing host defense mechanisms against Staphylococcus.
Purpose:
- To determine if a combination of Staphylococcus and RIL-2 confers resistance to lethal bacterial doses in a murine model.
- To elucidate the cellular and functional mechanisms underlying this induced resistance.
Summary:
- Mice treated with a non-lethal dose of Staphylococcus and RIL-2 developed resistance to subsequent lethal doses (3 DL100) within 6 days.
- This resistance is attributed to the activation of lymphoid tissues (lymph nodes, spleen), proliferation of liver stellate reticulo-endotheliocytes, and enhanced neutrophil phagocytic activity.
- The observed effects are likely mediated by direct RIL-2 actions and indirect signaling via other interleukins produced by RIL-2-activated lymphocytes.
Impact:
- Provides insights into potential therapeutic strategies using RIL-2 to bolster immune responses against bacterial pathogens.
- Highlights the complex interplay between cytokines and innate/adaptive immunity in overcoming infections.
- Suggests RIL-2 as a potential adjuvant for enhancing vaccine efficacy or antimicrobial treatments.